Program overview
Context
Indication: Metastatic Triple Negative Breast Cancers
Mechanism: Unknown
Modality: Unknown
Sponsor: Yale University
Watchlist Signal
Sacituzumab tirumotecan
Sacituzumab tirumotecan is flagged as watchlist signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07458113 | https://clinicaltrials.gov/study/NCT07193160 | https://clinicaltrials.gov/study/NCT07329322 | https://clinicaltrials.gov/study/NCT07343453 | https://clinicaltrials.gov/study/NCT06483334 | https://clinicaltrials.gov/study/NCT06637423
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07458113 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | strict_eligibility_signal |
| NCT07193160 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | rare_population_signal | strict_eligibility_signal |
| NCT07329322 | Low Signal (RECRUITING) | None | Low Signal | rare_population_signal |
| NCT07343453 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | rare_population_signal |
| NCT06483334 | Low Signal (ACTIVE_NOT_RECRUITING) | long_recruitment_duration_signal | Low Signal | strict_eligibility_signal |
| NCT06637423 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | None |